Naringenin ameliorates atopic dermatitis by inhibiting inflammation and enhancing immunity through the JAK2/STAT3 pathway|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Objective Atopic dermatitis (AD) is an inflammatory skin disease. Naringenin (Nar) possesses an anti-inflammatory property. This paper attempts to discuss the functional mechanism of Nar in AD mice through the Janus kinase 2 (JAK2)/signal transducer and activation of transcription 3 (STAT3) pathway.

Methods Mouse models of DNFB-induced AD were established and treated with Nar, followed by intraperitoneal injection with the JAK2/STAT3 pathway activator Coumermycin A1. Dermatitis severity was scored and the thickness of right ear was measured. The pathological changes in dorsal skin tissues were observed by HE staining. The number of infiltrated mast cells and eosinophilic granulocytes was counted by TB staining. The serum IgE level and levels of TNF-α, IL-6, IFN-γ, IL-12, and IL-5 in dorsal skin tissues were measured by ELISA. The levels of p-JAK2, JAK2, p-STAT3, and STAT3 were determined by Western blot.

Results Nar decreased dermatitis scores and right ear thickness, alleviated skin lesions, and reduced the number of infiltrated mast cells and eosinophilic granulocytes in AD mice. The serum IgE level and levels of TNF-α, IL-6, IFN-γ, IL-12, and IL-5 in dorsal skin tissues of AD mice were diminished after Nar treatment in a dose-dependent manner. Nar inhibited the activation of the JAK2/STAT3 pathway. The activation of the JAK2/STAT3 pathway partially nullified the therapeutic function of Nar on AD mice.

Conclusion Nar protects mice from AD by inhibiting inflammation and promoting immune responses through the inhibition of the JAK2/STAT3 pathway.

번역하기

참고문헌 (Reference)

1 Zeng H, "Viola yedoensis Makino formula allevi-ates DNCB-induced atopic dermatitis by activating JAK2/STAT3signaling pathway and promoting M2 macrophages polariza-tion" 103 : 154228-, 2022

2 Li H, "Update on the patho-genesis and therapy of atopic dermatitis" 61 : 324-338, 2021

3 Fishbein AB, "Update on atopic dermatitis : diagnosis, Severity Assessment, and treatment selection" 8 : 91-101, 2020

4 Jin W, "Topi-cal application of JAK1/JAK2 inhibitor momelotinib exhibits significant anti-inflammatory responses in DNCB-Induced atopic dermatitis model mice" 19 : 2018

5 Kim TH, "The inhibitory effect of naringenin on atopic dermatitis induced by DNFB in NC/Nga mice" 93 : 516-524, 2013

6 Tsiogka A, "The JAK/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: a systematic review" 11 : 2022

7 Howell MD, "Targeting the Janus kinase fam-ily in autoimmune skin Diseases" 10 : 2342-, 2019

8 Lee H, "TSLP down-regulates S100A7 and ss-defensin 2Via the JAK2/STAT3-Dependent mechanism" 136 : 2427-2435, 2016

9 Edslev SM, "Skin microbiome in atopic dermatitis" 100 : adv00164-, 2020

10 Chao L, "Shen-Ling-Bai-Zhu-San Improves Dextran Sodium Sulfate-Induced Colitis by Inhibiting Caspase-1/Cas-pase-11-Mediated Pyroptosis" 11 : 814-, 2020